Grand Rounds in Urology™ (GRU) publishes video presentations from world class thought leaders focu E. David Crawford, MD, serves as Medical Editor for GRU.
Grand Rounds in Urology™ (GRU) is a professional education organization with the mission of providing best practice and leading edge knowledge for the treatment of urologic disease. GRU has three primary educational functions:
Live Meetings: Organization and hosting of international conferences that bring together the top thought leaders in the treatment of urologic disease. GRU meetings focus on
04/01/2026
Save the date for the 30th Annual Innovations in Urologic Practice Conference! 🚨
Celebrating its 30th year, this conference offers a comprehensive look at today’s most important clinical topics, from bladder, prostate, and upper tract cancers to the growing role of immunotherapy, advanced imaging, MRI, and focal therapy.
📍 Inn & Spa at Loretto
📍 Santa Fe, New Mexico
📅 October 1st - 3rd, 2026
E. David Crawford, MD presents a case of an 81-year-old man with high-risk prostate cancer (initial PSA 8.4 ng/mL, Gleason 4+5=9), with a panel of PSMA PET experts.
PET Tumor Board Participants:
- Wayne Brisbane, MD, Assistant Professor of Urology, University of California, Los Angeles, Los Angeles, California.
- Daniel Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Yale School of Medicine, New Haven, Connecticut.
- Sean P. Collins, MD, PhD, Professor of Radiation Oncology, University of South Florida, Tampa, Florida.
- Andrew W. Hahn, MD, Assistant Professor of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
- Sherief H. Gamie, MD, Chief & Director, Molecular Imaging and Theranostics, Professor of Clinical Radiology, UC San Diego Health.
Watch the full discussion below! ⬇️
https://grandroundsinurology.com/pet-tumor-board-case-8/
Brought to you by Blue Earth Diagnostics, Inc. (U.S.)
11/12/2025
GRUroCast episode 7 is here! 🎙️
In this episode, An expert panel discusses emerging PET imaging technologies and intermittent versus continuous androgen deprivation therapy (ADT).
Contributors included:
- David Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York.
- Andrew W. Hahn, MD, Assistant Professor of Genitourinary Medical Oncology at the MD Anderson Cancer Center in Houston, Texas.
- Brian Helfand, MD, PhD, Chief of the Division of Urology, NorthShore University HealthSystem, Evanston, Illinois.
- Ronald Kaufman, Jr., MD, Associate Professor of Surgery in the department of Urology, Albany Medical College, Albany, New York.
- Christian Pavlovich, MD, Director of the Prostate Cancer Active Surveillance Program, Johns Hopkins, Baltimore, Maryland.
- Oliver Sartor, MD, Director of the Transformational Prostate Cancer Research Center, Metairie, Louisiana.
🎧 Listen Now: https://open.spotify.com/episode/4GfemP4I3aRzli2ygp6pwv?si=p7yJsDlFRt63Ng0NqagF1Q
Following the FDA's announcement for women's health, we would like to showcase this presentation by Rachel S. Rubin MD - Urologist and Sexual Medicine Specialist. Dr. Rubin reviews the latest evidence and FDA guidance following the removal of the Black Box warning on low-dose vaginal estrogen, providing practical insight into how clinicians can safely and effectively use intravaginal hormone therapy to restore vaginal health.
Watch the full presentation below! ⬇️
https://lnkd.in/e44VNsTB
09/05/2025
Episode 5 of the GRUroCast is now streaming! 🎉
To continue the theme of Prostate Cancer Awareness Month, this episode features a panel discussion on focal therapy, from The 35th International Prostate Cancer Update. The panel of experts explore the complexities of salvage treatment following focal therapy in prostate cancer.
Contributors include:
- Brian Davis, MD, PhD, Mayo Clinic, Rochester, Minnesota.
- John Davis, MD, University of Texas MD Anderson Cancer Center, Houston, Texas.
- Steven Frank, MD, FACR, FABS, FASTRO Professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Brian Helfand, MD, PhD, NorthShore University Health System, Evanston, Illinois.
- Peter Rossi, MD, Valley View Hospital, Glenwood Springs, California.
🎧 Listen now: https://open.spotify.com/episode/06DnsnH8OGQF8EtcMsC73r?si=m9tiZ9MdR5SIiKVAg32OBQ
September is Prostate Cancer Awareness Month 💙
We’re proud to share a special message from our Editor-in-Chief, E. David Crawford, MD, as he reflects on the origins of Prostate Cancer Awareness Month and why this movement remains so important today.
We encourage our community to use this month as an opportunity to come together and engage, educate, and support all whose lives are impacted by prostate cancer.
Register Now for the 12th Urology Today Conference, taking place October 31-November 2, 2025, at the beautiful and historic Omni Grove Park Inn in Asheville, North Carolina! 🍂
We’re excited to share a video from Program Director Ryan Terlecki, MD, FACS, who offers a preview of what makes this year’s CME event a must-attend for urologists, oncologists, and Advanced Practice Providers involved in urologic practice.
This year’s program is designed with your needs in mind:
- High-yield, 10–15 minute presentations from leading experts
- Half-day interactive sessions to maximize learning and leisure in Asheville
- Practical updates on benign & malignant disease, coding, reimbursement, and more!
Don’t wait and register below! ⬇️
https://www.eventbrite.com/e/12th-annual-urology-today-conference-registration-1270787482569?aff=oddtdtcreator
09/09/2024
Thanks for the share 94percent.com, and we were so excited to work with Garrett D Pohlman, M.D. on this webinar.
EpiSwitch® Prostate Screening (PSE) Blood Test Garrett D. Pohlman, MD, discusses his experience with the EpiSwitch® Prostate Screening (PSE) Blood Test, supported by Oxford BioDynamics.
03/03/2023
There is Still Time to Join Us for Hands-On Training at the Southwest Prostate Cancer Symposium, Westin Kierland Resort • Scottsdale, Arizona April 13-15, 2023. Register Now at https://hubs.ly/Q01D-yM80
03/03/2023
is a foundational Tx for , but the risk of cardiovascular complications can offset successful cancer treatment. E. David Crawford, MD, and Marc B. Garnick, MD, discuss the current state of ADT here:
Cardiovascular Complications in Patients Undergoing ADT | Video E. David Crawford, MD, and Marc B. Garnick, MD, discuss cardiovascular complications in patients on androgen deprivation therapy (ADT).
is an effective and well-tolerated treatment for locally advanced and metastatic . E. David Crawford, MD, , and Neal D. Shore, MD, address critical Tx questions, from managing T levels and dosing schedules to redefining .